AU2008301888A1 - Long interspersed nuclear element polypeptide compositions and methods of use thereof - Google Patents

Long interspersed nuclear element polypeptide compositions and methods of use thereof Download PDF

Info

Publication number
AU2008301888A1
AU2008301888A1 AU2008301888A AU2008301888A AU2008301888A1 AU 2008301888 A1 AU2008301888 A1 AU 2008301888A1 AU 2008301888 A AU2008301888 A AU 2008301888A AU 2008301888 A AU2008301888 A AU 2008301888A AU 2008301888 A1 AU2008301888 A1 AU 2008301888A1
Authority
AU
Australia
Prior art keywords
line
polypeptide
subject
individual
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008301888A
Other languages
English (en)
Inventor
Ashish Agrawal
Keith Garrison
Frederick M. Hecht
R. Bradley Jones
Duncan Meiklejohn
Douglas Nixon
Mario Ostrowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
J David Gladstone Institutes
University of California San Diego UCSD
Original Assignee
J David Gladstone Institutes
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J David Gladstone Institutes, University of California Berkeley, University of California San Diego UCSD filed Critical J David Gladstone Institutes
Publication of AU2008301888A1 publication Critical patent/AU2008301888A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
AU2008301888A 2007-09-20 2008-09-19 Long interspersed nuclear element polypeptide compositions and methods of use thereof Abandoned AU2008301888A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97399307P 2007-09-20 2007-09-20
US60/973,993 2007-09-20
PCT/US2008/010883 WO2009038756A2 (en) 2007-09-20 2008-09-19 Long interspersed nuclear element polypeptide compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2008301888A1 true AU2008301888A1 (en) 2009-03-26

Family

ID=40468692

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008301888A Abandoned AU2008301888A1 (en) 2007-09-20 2008-09-19 Long interspersed nuclear element polypeptide compositions and methods of use thereof

Country Status (11)

Country Link
US (1) US20110046042A1 (enExample)
EP (1) EP2200637A4 (enExample)
JP (1) JP2010539901A (enExample)
KR (1) KR20100075483A (enExample)
CN (1) CN101969987A (enExample)
AU (1) AU2008301888A1 (enExample)
BR (1) BRPI0817209A2 (enExample)
CA (1) CA2700115A1 (enExample)
MX (1) MX2010003110A (enExample)
RU (1) RU2010115088A (enExample)
WO (1) WO2009038756A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8647640B2 (en) 2009-06-24 2014-02-11 Richard E. COWART Vaccine compositions and methods of use to protect against infectious disease
US20140031250A1 (en) * 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
US20150219662A1 (en) * 2012-06-28 2015-08-06 University Of Louisville Research Foundation, Inc. Use of protein line-1 orf-1 as a biomarker for cancer
WO2014012165A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
WO2015200697A1 (en) 2014-06-25 2015-12-30 The General Hospital Corporation Targeting human satellite ii (hsatii)
WO2016159377A1 (ja) * 2015-04-03 2016-10-06 国立大学法人京都大学 がんの治療薬のスクリーニング方法
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
EP4045655A4 (en) * 2019-10-16 2024-02-28 King Abdullah University Of Science And Technology Methods for modulating human l1 retrotransposons rna and compositions for use therein
WO2021134040A2 (en) * 2019-12-26 2021-07-01 The Johns Hopkins University Enhancing expression of line-1 encoded orf2p for cancer therapeutics
WO2021246265A1 (ja) 2020-06-02 2021-12-09 学校法人東京女子医科大学 Ｓ１００ａ８阻害ペプチドとこれを含む疾患治療薬

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280108A (en) * 1991-09-27 1994-01-18 United States Of America Antibodies to p40
JP4125784B2 (ja) * 1995-10-20 2008-07-30 ユニバーシティ・オブ・ネブラスカ・ボード・オブ・リージェンツ 抗原提示細胞により仲介される免疫応答を高めるための組成物および方法
CN1315332A (zh) * 2000-03-27 2001-10-03 上海博德基因开发有限公司 一种新的多肽——l1－12和编码这种多肽的多核苷酸
CN1315379A (zh) * 2000-03-27 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人L1因子p40蛋白12和编码这种多肽的多核苷酸
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
CN1339478A (zh) * 2000-08-21 2002-03-13 上海博德基因开发有限公司 一种新的多肽——人l1因子orf2相关蛋白10.78和编码这种多肽的多核苷酸
CN1339450A (zh) * 2000-08-21 2002-03-13 上海博德基因开发有限公司 一种新的多肽——转座元蛋白14.41和编码这种多肽的多核苷酸
CN1343776A (zh) * 2000-09-19 2002-04-10 上海博德基因开发有限公司 一种新的多肽——dna聚合酶9.02和编码这种多肽的多核苷酸
CN1352094A (zh) * 2000-11-06 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人l1元件类蛋白19.80和编码这种多肽的多核苷酸
CN1425684A (zh) * 2001-12-19 2003-06-25 复旦大学 一种多肽——人反转录转座40蛋白－12.76和编码这种多肽的多核苷酸
AU2003294236A1 (en) * 2002-10-25 2004-05-25 Five Prime Therapeutics, Inc. Methods of use for novel human polypeptides encoded by polynucleotides
WO2005012502A2 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
AU2004291828B2 (en) * 2003-05-28 2010-09-23 The Johns Hopkins University Synthetic mammalian retrotransposon gene

Also Published As

Publication number Publication date
WO2009038756A3 (en) 2009-05-14
WO2009038756A2 (en) 2009-03-26
EP2200637A4 (en) 2011-10-19
JP2010539901A (ja) 2010-12-24
US20110046042A1 (en) 2011-02-24
KR20100075483A (ko) 2010-07-02
BRPI0817209A2 (pt) 2015-03-10
EP2200637A2 (en) 2010-06-30
CA2700115A1 (en) 2009-03-26
RU2010115088A (ru) 2011-10-27
MX2010003110A (es) 2010-05-19
CN101969987A (zh) 2011-02-09

Similar Documents

Publication Publication Date Title
US20110046042A1 (en) Long Interspersed Nuclear Element Polypeptide Compositions and Methods of Use Thereof
US20130323279A1 (en) Human Endogenous Retrovirus Polypeptide Compositions and Methods of Use Thereof
TWI473814B (zh) 有效控制豬繁殖及呼吸症候群之合成胜肽標記疫苗與檢測系統
WO2021163371A1 (en) Coronavirus t cell epitopes and uses thereof
JPH03503166A (ja) 抗ｈｉｖ応答を喚起する合成抗原
US10117922B2 (en) Dengue virus specific multiple HLA binding T cell epitopes for the use of universal vaccine development
US9572873B2 (en) Method of inducing a T lymphocyte response using T-cell immunogens derived from anti-viral proteins
Nardelli et al. Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide
US9474793B2 (en) Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus
US9486518B2 (en) Membrane proximal region of HIV GP41 anchored to the lipid layer of a virus-like particle vaccine
US20070253979A1 (en) Immunogenic Hiv Compositions and Related Methods
US20090041760A1 (en) Retroviral immunotherapy
Meyer et al. Hypervariable epitope construct: a synthetic immunogen that overcomes MHC restriction of antigen presentation
HK1135023A (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
WO2025117490A1 (en) Arenavirus t cell epitopes, megapools and uses thereof
WO2025064770A2 (en) Alphavirus t cell epitopes, megapools and uses thereof
AU2003200583B2 (en) A Retroviral Immunotherapy
AU2002258614B2 (en) Human papilloma virus immunoreactive peptides
JP2005506283A (ja) Ｎｅｆタンパク質起源のペプチド混合物、およびその応用
KR20070019635A (ko) 면역원성 ｈｉｖ 조성물 및 이와 관련된 방법

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period